Searched for
EVRYSDI
US Stocks: Biogen gets FDA approval for higher dose of genetic disorder drug, shares rise 3%The U.S. Food and Drug Administration has approved a higher dose of Biogen's spinal muscular atrophy drug Spinraza, the company said on M...- Roche Vs Natco: Supreme Court clears decks for launch of Natco Pharma's Risdiplam generic in IndiaThe Supreme Court has allowed Natco Pharma to launch its generic version of the spinal muscular atrophy drug Risdiplam in India, dismissing...
- Roche moves SC against Natco’s launch of generic Risdiplam in IndiaF. Hoffmann-La Roche AG has approached the Supreme Court. This follows a Delhi High Court decision permitting Natco Pharma to introduce a g...
- Natco wins patent battle to launch generic 'Risdiplam'A Delhi High Court ruling favors Natco Pharma against Roche's rare disease drug. Natco can now launch generic risdiplam, used for spinal mu...
- Delhi HC allows Natco Pharma to launch risdiplam, rejects Roche pleaThe Delhi High Court has permitted Natco Pharma to launch its affordable generic version of risdiplam, a crucial drug for spinal muscular a...
- Natco to sell rare spinal disease drug Risdiplam for ₹15,900Each bottle of Risdiplam lasts around 12 days and that will take the cost to roughly ₹30,000 per month for the patient. Sources said Roche ...
- Delhi HC asks Natco Pharma to pause Risdiplam launch amid patent disputeThe Delhi High Court has ordered Natco Pharma to maintain status quo on the launch of Risdiplam until April 2. Roche, which holds the paten...
- Delhi HC rejects Roche's plea to block Natco Pharma on Risdiplam patentThe Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy drug, citing pu...
- Budget 2025: 'Customs waiver on life-saving drugs won't benefit most patients'Despite the import duty waiver on life-saving drugs for rare diseases announced in the union budget, patients might not benefit due to high...
- Govt allows global tenders to access 120 key, patented drugsIn what could ease access to some patented medicines, the government has allowed global tenders to be floated for procurement of 120 drugs,...
- GST exemption on medicines for rare diseases is unlikely to provide any relief to those in need: Health activistsThe recent GST exemption on medicines for rare diseases in India is unlikely to help many patients as the drugs are still too expensive, sa...
- Supreme Court dismisses petition seeking removal of GST, customs duty on medicines to cure spinal muscular atrophyCure SMA Foundation of India, a parent-led organisation, had approached the court seeking exemption of GST and customs duty on treatment of...
- Pharma companies' charity hope for kids with rare spinal disorderThe rare disease affects one in every 8,000 children. The bigger problem, according to parents and doctors, is the lack of awareness about ...
- Roche launches spinal muscular atrophy treatment drug in India priced at around Rs 6 lakh per bottleSince its launch, over 4,000 SMA patients across over 50 countries have benefitted from the drug, Roche said in a statement.
Load More
